A type of NMN microcapsule, its preparation method and application

By constructing NMN microcapsules using nonionic neutral polysaccharide framework materials, the problem of low bioavailability of oral NMN formulations was solved, achieving stable protection in the stomach and long-lasting release in the small intestine, thus improving the oral absorption of NMN.

CN123100830APending Publication Date: 2026-11-17JIANG SU PHARMAMAXCORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611263970.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing oral NMN formulations have low bioavailability and insufficient gastrointestinal stability, making it difficult to achieve sustained release and effectively block intestinal flora metabolism.

Method used

NMN microcapsules are constructed using non-ionic neutral polysaccharide backbone materials. A continuous three-dimensional gel network is formed through an extrusion and spheroidization process to maintain a microenvironment with a pH of 6.0~7.5 inside the microcapsules, achieving stable protection in the stomach and long-lasting sustained release in the small intestine.

Benefits of technology

It significantly improves the oral bioavailability of NMN, reduces gastric acid degradation, prolongs intestinal residence time, blocks intestinal flora metabolism, and improves blood drug concentration stability and total exposure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention belongs to the field of dietary supplements and pharmaceutical preparations, specifically relating to an NMN microcapsule, its preparation method, and its application. The NMN microcapsule provided by this invention uses non-ionic neutral polysaccharides as the microcapsule framework material. Spherical microcapsules are prepared through an extrusion and spherical rolling process, forming a continuous three-dimensional gel network within the microcapsule. This network autonomously maintains a stable neutral microenvironment, achieving good gastric stability and small intestinal sustained-release effect without relying on an enteric-coated capsule shell. This effectively reduces NMN degradation and metabolic loss in the gastrointestinal tract, significantly improving oral bioavailability. All raw materials used in this invention are food-grade, and the preparation process is simple and controllable, suitable for large-scale production. It can be widely applied in the field of dietary supplements that increase NAD+ levels and improve metabolism.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of dietary supplements and pharmaceutical preparations, specifically relating to an NMN microcapsule, its preparation method, and its application. Background Technology

[0002] Nicotinamide mononucleotide (NMN) is a direct precursor of nicotinamide adenine dinucleotide (NAD+), which can effectively increase NAD+ levels in the body. It plays an important physiological role in improving metabolism and protecting nerve function, making it a hot research topic in the field of dietary supplements. Oral administration is the most common route of NMN administration, but its low oral bioavailability limits its full efficacy.

[0003] The oral absorption of NMN faces multiple bottlenecks: it is easily degraded in the acidic environment of the stomach, making it difficult to reach the absorption site in the small intestine intact; NMN is a small molecule, which has a short residence time in the intestine, and the absorption process depends on specific transporters, making it prone to saturation; related enzymes expressed by intestinal flora can decompose and metabolize unprotected NMN; conventional formulations have a fast release rate, large fluctuations in blood drug concentration, and are easily affected by the first-pass effect of the liver and are rapidly eliminated.

[0004] To alleviate these issues, the industry has developed solutions using enteric coating and solid dispersion technologies to improve the oral performance of NMN. Enteric coating primarily provides gastric protection through an outer coating layer; however, once the coating dissolves in the intestines, the drug is exposed to the intestinal environment, making sustained release difficult and hindering the metabolic effects of gut microbiota. Another approach involves ionic polysaccharide encapsulation, but its structure and performance are significantly affected by the gastrointestinal environment, resulting in insufficient overall stability and difficulty in providing sustained protection. Summary of the Invention

[0005] To address the shortcomings of existing technologies, this invention provides an NMN microcapsule, its preparation method, and its application.

[0006] The purpose of this invention is to solve the problems of low bioavailability and insufficient gastrointestinal stability of existing oral NMN preparations, and to improve their oral absorption and overall performance.

[0007] The first aspect of the present invention provides an NMN microcapsule, which is made by filling NMN neutral polysaccharide microcapsules into a capsule shell; the NMN neutral polysaccharide microcapsules, by weight percentage, comprise the following components: 10%~30% NMN, 60%~85% nonionic neutral polysaccharide backbone material, 2%~9% binder, and 0.5%~1.5% lubricant.

[0008] Among them, the non-ionic neutral polysaccharide backbone material does not contain free acidic groups and forms a continuous three-dimensional gel network inside the microspheres, constructing and maintaining a microenvironment with a pH of 6.0~7.5 inside the microspheres; the non-ionic neutral polysaccharide backbone material is selected from one or more combinations of konjac glucomannan, yeast-derived β-glucan, oat-derived β-glucan, tamarind polysaccharide gum, guar gum, and locust bean gum.

[0009] More preferably, the NMN neutral polysaccharide microspheres comprise, by weight percentage, the following components: 15%~25% NMN, 37%~80% nonionic neutral polysaccharide backbone material, 4%~8% binder, and 0.8%~1.2% lubricant.

[0010] In some preferred NMN microcapsules, the nonionic neutral polysaccharide backbone material is a compound of konjac glucomannan and yeast-derived β-glucan, with a weight ratio of (3~5):1.

[0011] Furthermore, the nonionic neutral polysaccharide framework material also includes tamarind polysaccharide gum, konjac glucomannan, yeast-derived β-glucan and tamarind polysaccharide gum in a weight ratio of (3~5):1:(0.5~1).

[0012] In some preferred NMN microcapsules, the nonionic neutral polysaccharide backbone material is a compound of konjac glucomannan, oat-derived β-glucan, guar gum and guar gum, with a weight ratio of (3~5):1:(1.5~2.5):(0.8~1.2).

[0013] In some preferred NMN microcapsules, the binder is selected from one or a combination of two of hydroxypropyl methylcellulose and povidone; the binder is added in the form of an aqueous solution.

[0014] In some preferred NMN microcapsules, the lubricant is selected from one or a combination of two of magnesium stearate, talc, and micronized silica gel.

[0015] In some preferred NMN microcapsules, the capsule shell is a gelatin hard capsule or an HPMCP enteric-coated capsule shell; the HPMCP enteric-coated capsule shell does not dissolve in an environment with pH < 5.0, but dissolves completely within 10 minutes in an environment with pH ≥ 5.5.

[0016] A second aspect of the present invention provides a method for preparing the above-mentioned NMN microcapsules, comprising the following steps: S1. Mixing to form a soft material: Take NMN and non-ionic neutral polysaccharide framework material, mix them evenly, add adhesive aqueous solution, and stir to form a soft material; S2. Preparation of microspheres: The soft material is shaped into spherical microspheres and dried; S3. Mixed Lubrication: Add the prescribed amount of lubricant to the dried micro-pellets and mix thoroughly; S4. Filling capsules: Fill the mixed micro-pellets into capsule shells to obtain the finished product.

[0017] As a further optimization of the above preparation method, a raw material pretreatment step is included before step S1: NMN and non-ionic neutral polysaccharide framework material are crushed and sieved separately for later use.

[0018] As a further optimization of the above preparation method, in step S2, the soft material is extruded into strips and then rolled into spherical microspheres; the extrusion is carried out using a screw extruder with a screw speed of 25~40 rpm and an extrusion orifice diameter of 0.8~1.0 mm; the rolling speed is 400~600 rpm and the rolling time is 8~12 minutes, and the sphericity of the obtained microspheres is ≥0.9.

[0019] As a further optimization of the above preparation method, in step S4, the NMN content in each capsule is controlled to be 100~200mg.

[0020] The third invention provides an application of the above-mentioned NMN microcapsule in the preparation of a dietary supplement for increasing NAD+ levels in the body.

[0021] Beneficial effects Compared with existing technologies, the high bioavailability NMN neutral polysaccharide microcapsules provided by this invention, through the synergistic effect of screening and compounding non-ionic neutral polysaccharide framework materials and extrusion spheronization preparation process, construct a continuous and stable three-dimensional gel network structure within the microcapsules. This structure can autonomously maintain a neutral microenvironment within the microcapsules, and possesses multiple functions such as gastric stability protection, long-term sustained release in the small intestine, and intestinal flora metabolic barrier, significantly improving the oral bioavailability of NMN. All raw materials used in this invention are food-grade, ensuring good safety and compliance. The preparation process is simple and controllable, suitable for large-scale industrial production, and can be widely applied in the field of dietary supplements to increase NAD+ levels in the body. Detailed Implementation

[0022] The present invention is further illustrated below with specific embodiments. These embodiments are exemplary and intended to illustrate the problem and explain the present invention, and are not intended to be limiting.

[0023] Example 1 A neutral polysaccharide NMN microcapsule, by weight percentage, comprises: 20% NMN, 56% konjac glucomannan, 15% yeast-derived β-glucan, 8% hydroxypropyl methylcellulose, 0.5% magnesium stearate, and 0.5% micronized silica gel; the capsule shell is a regular gelatin hard capsule, and each capsule contains 150mg of NMN.

[0024] Preparation method: S1. Crush NMN, konjac glucomannan, and yeast-derived β-glucan separately, pass them through an 80-mesh sieve, and set aside. S2. Weigh the above raw and auxiliary materials according to the prescription amount, place them in a mixer and mix for 15 minutes until evenly mixed; S3. Prepare an aqueous solution of HPMCE5 as a binder, add it to the mixed powder, and stir to form a soft material; S4. Place the soft material in the screw extruder, with a screw speed of 30 rpm and an extrusion orifice diameter of 0.8 mm, and extrude it into uniform strip-shaped material; S5. Immediately transfer the strip-shaped material to a pelletizing machine at 500 rpm for 10 minutes to form micro-pellets; dry until the moisture content is ≤3%. S6. Add the prescribed amount of micronized silica gel and magnesium stearate to the dried microspheres and mix for 5 minutes. S7. Fill the mixed microspheres into ordinary gelatin hard capsules. Each capsule contains 150mg of NMN to obtain the finished product.

[0025] Example 2 A neutral polysaccharide microcapsule for NMN, comprising, by weight percentage: 25% NMN, 45% konjac glucomannan, 12% yeast-derived β-glucan, 10% tamarind polysaccharide gum, 7% povidone, 0.75% micronized silica gel, and 0.25% talc; the capsule shell is a regular gelatin hard capsule, and each capsule contains 150mg of NMN.

[0026] Preparation method: S1. Crush NMN, konjac glucomannan, yeast-derived β-glucan, and tamarind polysaccharide gum separately, pass them through an 80-mesh sieve, and set aside. S2. Weigh the above raw and auxiliary materials according to the prescription amount, place them in a mixer and mix for 15 minutes until evenly mixed; S3. Prepare a PVPK30 aqueous solution as an adhesive, add it to the mixed powder, and stir to form a soft material; S4. Place the soft material in the screw extruder, with a screw speed of 40 rpm and an extrusion orifice diameter of 0.9 mm, and extrude it into uniform strip-shaped material; S5. Immediately transfer the strip-shaped material to a rounding machine, rotate at 600 rpm, round for 8 minutes to form micro pellets, dry to a moisture content of ≤3%, and collect qualified micro pellets. S6. Add the prescribed amount of micronized silica gel and talc to the dried microspheres and mix for 5 minutes. S7. Fill the mixed microspheres into ordinary gelatin hard capsules. Each capsule contains 150mg of NMN to obtain the finished product.

[0027] Example 3 A neutral polysaccharide NMN microcapsule, by weight percentage, comprises: 15% NMN, 40% konjac glucomannan, 10% oat-derived β-glucan, 20% guar gum, 10% guar gum, 4% hydroxypropyl methylcellulose, 0.5% talc, and 0.5% magnesium stearate; the capsule shell is a regular gelatin hard capsule, and each capsule contains 150mg of NMN.

[0028] Preparation method: S1. Grind NMN, konjac glucomannan, oat-derived β-glucan, guar gum, and guar gum separately, and pass them through an 80-mesh sieve for later use. S2. Weigh the above raw and auxiliary materials according to the prescription amount, place them in a mixer and mix for 20 minutes until evenly mixed; S3. Prepare an aqueous solution of HPMCE5 as a binder, add it to the mixed powder, and stir to form a soft material; S4. Place the soft material in the screw extruder, with a screw speed of 25 rpm and an extrusion orifice diameter of 1.0 mm, and extrude it into uniform strip-shaped material; S5. Immediately transfer the strip-shaped material to a rounding machine at a speed of 400 rpm for 12 minutes to form micro pellets. Dry the pellets until the moisture content is ≤3% and collect them. S6. Add the prescribed amount of talc and magnesium stearate to the dried microspheres and mix for 5 minutes. S7. Fill the mixed microspheres into ordinary gelatin hard capsules. Each capsule contains 150mg of NMN to obtain the finished product.

[0029] Example 4 A neutral polysaccharide NMN microcapsule is prepared. The microcapsule formulation is completely consistent with that in Example 1, except that the capsule shell is replaced with an HPMCP enteric-coated capsule shell. Each capsule contains 150 mg of NMN, and the rest of the preparation method is the same as in Example 1.

[0030] Comparative Example 1 Regular NMN hard capsules: NMN powder is directly filled into a regular gelatin capsule shell, and each capsule contains 150mg of NMN.

[0031] Comparative Example 2 Regular NMN enteric-coated capsules: NMN powder is directly filled into HPMCP enteric-coated capsule shells, with each capsule containing 150mg of NMN.

[0032] Comparative Example 3 The conventional enteric-coated microcapsule is composed of 20% NMN, 72% microcrystalline cellulose, 7% povidone K30, and 1% magnesium stearate. The microcapsules are coated with Opadry enteric coating powder, resulting in an 8% weight gain. The capsule shell is a regular gelatin hard capsule, and each capsule contains 150mg of NMN.

[0033] Preparation method: NMN, MCC, and PVPK30 were mixed to prepare a soft material, which was then extruded and spheroidized to prepare drug-loaded microspheres, and dried to a moisture content of ≤3%. Enteric coating was performed using a fluidized bed bottom spraying process, resulting in an 8% weight gain from the coating. After drying, the product was granulated. Add magnesium stearate as a lubricant and fill with ordinary gelatin hard capsules.

[0034] Comparative Example 4 Sodium alginate skeleton microcapsules, the microcapsule components are: 20% NMN, 55% sodium alginate, 15% calcium alginate, 8% HPMCE5, 0.5% magnesium stearate; the capsule shell is a regular gelatin hard capsule, each capsule contains 150mg of NMN.

[0035] The preparation method is the same as in Example 1, except that the neutral polysaccharide is replaced with a sodium alginate system.

[0036] Comparative Example 5 NMN and neutral polysaccharide physical mixture capsules, the composition of which is: 20% NMN, 55% konjac glucomannan, 15% yeast-derived β-glucan, 8% HPMCE5, 0.5% magnesium stearate; the capsule shell is a regular gelatin hard capsule, each capsule contains 150mg of NMN.

[0037] Preparation method: Pass all raw and auxiliary materials through an 80-mesh sieve, mix them physically for 15 minutes until uniform, and directly fill them into ordinary gelatin hard capsules without extrusion or spheroidization to form micro-pellets.

[0038] Comparative Example 6 HPMC sustained-release microcapsule capsules contain the following components: 20% NMN, 70% HPMCK15M, 7% microcrystalline cellulose, 2.5% PVPK30, and 0.5% magnesium stearate. The capsule shell is a regular gelatin hard capsule, and each capsule contains 150mg of NMN.

[0039] The preparation method is the same as in Example 1, except that the neutral polysaccharide is replaced with HPMCK15M.

[0040] Test Example 1: In vitro dissolution test In vitro dissolution tests were conducted using Method 1 of General Chapter 4, Volume 4, Chinese Pharmacopoeia 2025 Edition.

[0041] Medium: 900 ml of 0.1 mol / L hydrochloric acid solution, replaced with 900 ml of pH 6.8 phosphate buffer solution after 2 hours; rotation speed: 75 rpm; temperature: 37℃±0.5℃; sampling times: 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h. Table 1. In vitro dissolution rates of different formulations As shown in Table 1, Examples 1-3, using ordinary gelatin capsules, all exhibited a release rate of less than 6% in acidic conditions after 2 hours, comparable to the gastric protection effect of Comparative Example 2. This demonstrates that the neutral polysaccharide microspheres prepared in this invention can achieve gastric acid resistance comparable to enteric-coated capsules without relying on enteric coating. Comparative Example 3, using a conventional enteric-coated microsphere scheme with microcrystalline cellulose as the backbone and an outer enteric coating, showed rapid release under neutral conditions and did not provide a sustained-release effect. Comparative Example 4, using ionic polysaccharide sodium alginate as the backbone material, achieved a release rate of 30.7% in acidic conditions after 2 hours, significantly higher than that of this invention. This indicates that the gel structure of the ionic polysaccharide scheme is damaged in acidic environments, failing to maintain the internal microenvironment. Comparative Example 5 had the same formulation as Example 1, but without extrusion and spheronization processes; it was simply a physical mixture of NMN and neutral polysaccharide powder directly filled into capsules, resulting in a release rate as high as 89.0% in acidic media after 2 hours. This indicates that the above formulation requires the extrusion and spheronization method of the present invention to form a stable, continuous three-dimensional gel network and exert the protective and sustained-release effects of neutral polysaccharides. If polysaccharides are added only through simple physical mixing, a stable continuous gel barrier encapsulating NMN cannot be constructed to resist acidic environments. The formulation in Example 4 is based on the microcapsule formulation of Example 1, but replaces the ordinary gelatin capsule shell with an HPMCP enteric-coated capsule shell, which results in the lowest release in acid and achieves a dual protective effect.

[0042] Experimental Example 2: Bioavailability Test in Rats Thirty healthy male SD rats, weighing 200-220g, were randomly divided into 5 groups of 6 rats each. Each group was administered the formulations of Example 1, Comparative Example 1, Comparative Example 2, and Comparative Example 6 by gavage, with a dosage of 100mg / kg. Blood samples were collected at 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h, and 24h after administration. Plasma concentrations of NMN were measured, and pharmacokinetic parameters were calculated. The results are shown in Table 2.

[0043] Table 2 NMN blood concentration detection data Table 2 shows the pharmacokinetic results in rats, indicating significant differences in absorption rate, peak concentration characteristics, and total exposure among different formulations. The AUC0₋ of Example 1... 24hThe bioavailability reached 2156.8 ng·h / ml, approximately four times that of Comparative Example 1; simultaneously, Cmax increased from 156.8 ng / ml to 287.6 ng / ml, and Tmax was significantly delayed from 0.7 h to 5.2 h. Comparative Example 1 used a direct-filling scheme with pure drug powder in ordinary hard capsules, without further protection or sustained-release structures. NMN rapidly dissolved and degraded in the stomach, quickly reaching peak levels in the bloodstream and then being rapidly cleared due to the first-pass effect in the liver, resulting in extremely low total exposure. The formulation of this invention achieves both gastric stability and intestinal sustained release through a neutral polysaccharide three-dimensional gel network. This reduces drug degradation losses caused by gastric acid and prolongs the drug's residence time at the small intestinal absorption sites through slow release, reducing the impact of transporter saturation and the first-pass effect in the liver, ultimately achieving a significant increase in total bioavailability.

[0044] Compared with Comparative Example 2, the AUC0₋ of Example 1 24h Approximately 2.5 times that of the former, Tmax was extended from 2.5 h to 5.2 h. Comparative Example 2 relied on the enteric-coated capsule shell to resist gastric acid, but the rapid release of NMN after the capsule shell dissolved in the intestines still faced bottlenecks such as short intestinal residence time, easy saturation of transporters, and a strong first-pass effect, thus limiting the overall increase in exposure. Enteric protection alone can only eliminate some obstacles to the oral absorption of NMN and cannot fundamentally improve bioavailability.

[0045] Compared with Comparative Example 3, the AUC0₋ of Example 1 24h The effect was improved by approximately 60%, and the Tmax was extended from 2.1 h to 5.2 h. Comparative Example 3 used a microcrystalline cellulose backbone with an outer enteric coating. After the coating dissolved in the intestine, the drug was rapidly released along with the inert backbone, resulting in limited sustained-release effect. Furthermore, this approach could not construct a stable neutral microenvironment within the microspheres, nor could it form a dense barrier to block the metabolic activity of intestinal flora; the total exposure was still significantly lower than that of this invention. These results indicate that the self-protection and sustained-release mechanism of this invention, based on an internal three-dimensional gel network, is superior to the traditional enteric-coated microsphere technology using an outer coating combined with an inert backbone.

[0046] Compared with Comparative Example 6, the AUC0₋ of Example 1 24The time to Tmax (h) was approximately twice that of Comparative Example 6. Although Comparative Example 6 achieved a Tmax of 3.7 h, demonstrating some sustained-release effect, its total exposure was even lower than that of Comparative Example 3, which had an enteric coating. The reason for this is that HPMC can only exert a kinetic regulation effect on the skeletal sustained-release mechanism through swelling; it cannot effectively block the penetration of acidic mediators in the stomach, maintain a neutral microenvironment to prevent drug degradation, or form a dense physical barrier to prevent the decomposition of NMN by intestinal flora nucleoside hydrolases. This result clearly indicates that sustained-release capability is only a necessary condition, not a sufficient condition, for improving NMN bioavailability; only by simultaneously possessing multiple functions such as gastric stability protection, a neutral internal microenvironment, long-term sustained release in the intestine, and metabolic barrier effects can a significant improvement in the oral bioavailability of NMN be achieved.

[0047] Test Example 3: Stability Test Examples 1-3 were subjected to long-term stability tests at 30℃±2℃ and relative humidity of 65%±5%, and the NMN content was detected. The results are summarized in Table 3.

[0048] Table 3 Results of Long-Term Stability Test As shown in Table 3, after 12 months of long-term stability testing, the NMN content of Examples 1-3 remained above 95%, meeting the quality control requirements. This also indicates that the present invention not only improves the oral bioavailability of NMN, but also ensures the stable storage of NMN.

[0049] The above embodiments are exemplary and are intended to illustrate the technical concept and features of the present invention, so that those skilled in the art can understand the content of the present invention and implement it accordingly. They should not be construed as limiting the scope of protection of the present invention. All equivalent changes or modifications made according to the spirit and essence of the present invention should be covered within the scope of protection of the present invention.

Claims

1. An NMN microcapsule, characterized in that, It is manufactured by filling NMN neutral polysaccharide microspheres into capsule shells; the NMN neutral polysaccharide microspheres comprise the following components by weight percentage: 10%~30% NMN, 60%~85% nonionic neutral polysaccharide backbone material, 2%~9% binder, 0.5%~1.5% lubricant; The nonionic neutral polysaccharide backbone material does not contain free acidic groups, and the nonionic neutral polysaccharide backbone material is selected from one or more combinations of konjac glucomannan, yeast-derived β-glucan, oat-derived β-glucan, tamarind polysaccharide gum, guar gum, and locust bean gum.

2. The NMN microcapsule according to claim 1, characterized in that, The nonionic neutral polysaccharide backbone material is a compound of konjac glucomannan and yeast-derived β-glucan, with a weight ratio of (3~5):

1.

3. The NMN microcapsule according to claim 2, characterized in that, The nonionic neutral polysaccharide framework material also includes tamarind polysaccharide gum, and the weight ratio of konjac glucomannan, yeast-derived β-glucan and tamarind polysaccharide gum is (3~5):1:(0.5~1).

4. The NMN microcapsule according to claim 1, characterized in that, The nonionic neutral polysaccharide backbone material is a compound of konjac glucomannan, oat-derived β-glucan, guar gum and guar gum, with a weight ratio of (3~5):1:(1.5~2.5):(0.8~1.2).

5. The NMN microcapsule according to claim 1, characterized in that, The adhesive is selected from one or a combination of two of hydroxypropyl methylcellulose and povidone; the adhesive is added in the form of an aqueous solution; the lubricant is selected from one or a combination of two of magnesium stearate, talc, and micronized silica gel.

6. The NMN microcapsule according to claim 1, characterized in that, The capsule shell is a gelatin hard capsule shell or an HPMCP enteric-coated capsule shell.

7. A method for preparing NMN microcapsules, characterized in that, Includes the following steps: S1. Mixing to form a soft material: Take NMN and non-ionic neutral polysaccharide framework material, mix them evenly, add adhesive aqueous solution, and stir to form a soft material; S2. Preparation of microspheres: The soft material is shaped into spherical microspheres and dried; S3. Mixed Lubrication: Add the prescribed amount of lubricant to the dried micro-pellets and mix thoroughly; S4. Filling capsules: Fill the mixed micro-pellets into capsule shells to obtain the finished product; The NMN neutral polysaccharide microspheres, by weight percentage, comprise the following components: 10%~30% NMN, 60%~85% nonionic neutral polysaccharide backbone material, 2%~9% binder, and 0.5%~1.5% lubricant. The nonionic neutral polysaccharide backbone material does not contain free acidic groups, and the nonionic neutral polysaccharide backbone material is selected from one or more combinations of konjac glucomannan, yeast-derived β-glucan, oat-derived β-glucan, tamarind polysaccharide gum, guar gum, and locust bean gum.

8. The preparation method according to claim 7, characterized in that, Before step S1, there is also a raw material pretreatment step: NMN and non-ionic neutral polysaccharide backbone material are crushed and sieved separately for later use.

9. The preparation method according to claim 7, characterized in that, In step S2, the soft material is extruded into strips and then rolled into spherical microspheres. The extrusion is performed using a screw extruder with a screw speed of 25-40 rpm and an extrusion orifice diameter of 0.8-1.0 mm. The rolling speed is 400-600 rpm and the rolling time is 8-12 minutes. The resulting microspheres have a sphericity ≥0.

9.

10. An application of an NMN microcapsule, characterized in that, The NMN microcapsules are NMN microcapsules according to any one of claims 1 to 6, or NMN microcapsules prepared by the preparation method according to any one of claims 7 to 9; the NMN microcapsules are used in the preparation of dietary supplements for increasing NAD+ levels in the body.